Affluent Medical SA (FR:AFME) has released an update.
Affluent Medical has announced the successful activation of its Artus artificial urinary sphincter in the first two patients of the European ‘Dry’ pilot study, indicating progress towards their goal for the year. This innovation by the French MedTech company aims to address the pressing medical need for effective urinary incontinence treatments, a market projected to grow significantly by 2027. The company’s strategy, subject to funding and positive clinical study outcomes, includes a product commercialization plan starting from early 2026.
For further insights into FR:AFME stock, check out TipRanks’ Stock Analysis page.
